SEPTInvestingStart Free

RXRX 424B5: Secondary offering

Recursion Pharmaceuticals

Filed with the SEC on · accession 0001601830-26-000126

RXRX filed a 424B5 (prospectus (offering)) with the SEC on Oct 15, 2026. The final terms of an offering of shares or bonds. The stock moved +11.2% by the first close after the filing.

Summary of the filing

Recursion Pharmaceuticals filed a preliminary prospectus supplement for a $200 million public offering of its Class A Common Stock, with Leerink Partners, Goldman Sachs, Morgan Stanley, Evercore ISI, and Needham & Company as underwriters.

For details, click here →How to read a 424B5 →

Key details

Total offering amount$200.0M
Last reported sale price per share on October 14, 2026$4
IssuerRecursion Pharmaceuticals, Inc.
UnderwriterLeerink Partners
UnderwriterGoldman Sachs & Co. LLC
UnderwriterMorgan Stanley
UnderwriterEvercore ISI
UnderwriterNeedham & Company

How RXRX stock reacted

Close before

$3.74

Oct 14, 2026

First close after

+11.23%

$4.16

5 trading days

-2.67%

$3.64

Since filing

-5.08%

$3.55

✦ Ask GOAX AI about this filing — what it means for RXRX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for RXRX?

Click here

Frequently asked questions

What did RXRX file with the SEC on Oct 15, 2026?

RXRX filed a 424B5 (Secondary offering). Recursion Pharmaceuticals filed a preliminary prospectus supplement for a $200 million public offering of its Class A Common Stock, with Leerink Partners, Goldman Sachs, Morgan Stanley, Evercore ISI, and Needham & Company as underwriters.

What does a secondary offering mean for RXRX stock?

New shares dilute existing holders and are often sold at a discount to the market price.

How do I read a 424B5?

The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B5 (prospectus (offering)): The final terms of an offering of shares or bonds.

How did RXRX stock react to this filing?

RXRX closed at $3.74 before the filing and $4.16 on Oct 15, 2026 (+11.23%). Five trading days later: $3.64 (-2.67%).

Other RXRX SEC filings

Get alerts when RXRX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
RXRX overviewRXRX analysisRXRX newsLatest SEC filings